Sign In
Buy SRPT
$16.66
+0.420 (+2.59%)
At Close: Jun 04, 2026
Could Sarepta Therapeutics Become the Next Vertex Pharmaceuticals?
09:45am, Thursday, 25'th Jan 2024
Sarepta Therapeutics and Vertex Pharmaceuticals both go after rare diseases. Sarepta has made headway in its core area, but there is more work to be done.
Sarepta Therapeutics: Leading The Way In DMD Treatment With Gene Therapy Innovations
04:31am, Wednesday, 24'th Jan 2024
Sarepta Therapeutics is a biopharmaceutical company focused on developing gene therapy and RNA-targeted treatments for rare diseases such as Duchenne muscular dystrophy and Limb-girdle muscular dystro
Sarepta Therapeutics Inc.: Why it's a rising gene therapy star
07:21am, Tuesday, 23'rd Jan 2024
Sarepta Therapeutics Inc. NASDAQ: SRPT is a leading commercial-stage biotech focused on developing precision gene therapy treatments for rare diseases. This medical sector company specializes in
Why Sarepta Therapeutics Stock Zoomed Nearly 5% Higher Today
05:47pm, Monday, 22'nd Jan 2024
An analyst made a major change to his take on the biotech. He raised his price target considerably.
Wall Street Analysts Think Sarepta Therapeutics (SRPT) Could Surge 29.51%: Read This Before Placing a Bet
10:56am, Monday, 22'nd Jan 2024
The consensus price target hints at a 29.5% upside potential for Sarepta Therapeutics (SRPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earni
Catalyst Countdown: 3 Biotech Stocks With Upcoming News That Could Move the Market
03:57pm, Tuesday, 16'th Jan 2024
For many biotech stocks, price and performance hinges on the success of a drug in testing. This means most biotech companies rely on one market opportunity to succeed financially.
Why Sarepta's (SRPT) Stock Price Moved Up 17% on Tuesday
02:17pm, Wednesday, 10'th Jan 2024
Sarepta (SRPT) surges after its CEO made positive comments on the label expansion filing for the company's DMD gene therapy. The company expects a potential approval in August.
Sarepta Rebounded. Its Gene Therapy Is Back on Course.
11:43am, Wednesday, 10'th Jan 2024
The future of Sarepta Therapeutics' gene therapy for Duchenne muscular dystrophy looked grim two months ago. There's been a 180 since.
5 Mid-Cap Stocks to Buy in a Volatile January
09:46am, Wednesday, 10'th Jan 2024
We have narrowed our search to five mid-caps that have strong potential for 2024. These are: DVA, MNDY, GTLB, LNW, SRPT.
Sarepta Therapeutics (SRPT) Surges 16.7%: Is This an Indication of Further Gains?
07:31am, Wednesday, 10'th Jan 2024
Sarepta Therapeutics (SRPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near
Sarepta (SRPT) Rises on Solid Q4 and 2023 Preliminary Results
12:02pm, Tuesday, 09'th Jan 2024
Sarepta (SRPT) issues encouraging preliminary results for the fourth quarter and full-year 2023. Shares of the company rise.
Why Is Sarepta Therapeutics (SRPT) Stock Up Today?
11:22am, Tuesday, 09'th Jan 2024
Sarepta Therapeutics (NASDAQ: SRPT ) stock is rising higher on Tuesday after positive comments were made by its CEO at the JPMorgan Healthcare Conference. Sarepta Therapeutics CEO Douglas Ingram said
2 Growth Stocks That Could Make You Richer in 2024 and Beyond
07:15am, Tuesday, 09'th Jan 2024
Sarepta Therapeutics boasts excellent innovative abilities and a deep pipeline. DexCom still has a huge growth runway left in the continuous glucose monitoring market.
3 Top Biotech Stocks Worth Adding to Your Portfolio in 2024
11:18am, Friday, 05'th Jan 2024
REGN, BGNE & SRPT are three biotech companies that are likely to outperform the sector on the back of strong fundamentals.
Dyne Therapeutics stock gains, Sarepta falls after muscular dystrophy trial results
08:19am, Wednesday, 03'rd Jan 2024
Dyne Therapeutics Inc. shares DYN, -1.80% jumped 40% premarket on Wednesday after the company released new data from trials of two investigational treatments for genetic muscle disorders. The experime
